Vancouver-based biotech Cardiome Pharma Corp.’s future seems unclear, even to its own management, following the decision on March 17 of its partner, Merck & Co. Inc., to discontinue development of its lead project, an oral version of the anti-arrhythmic drug vernakalant.
Cardiome’s share price plummeted by more than 50% and the status of the development project fell into limbo after it announced Merck’s decision on March 19. Several analysts have since downgraded the stock, citing the company’s lack of options going forward
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?